<DOC>
	<DOCNO>NCT02451969</DOCNO>
	<brief_summary>The purpose study evaluate immunogenicity safety investigational 23-valent pneumococcal polysaccharide vaccine ( PPV ) healthy child , adult elderly . The control vaccine commercialize 23-valent PPV .</brief_summary>
	<brief_title>Safety Immunogenicity Study 23-valent Pneumococcal Polysaccharide Vaccine Healthy Children , Adults Elderly</brief_title>
	<detailed_description>This study randomize , double-blind , single-center , controlled phase III clinical trial . The purpose study evaluate immunogenicity safety investigational 23-valent pneumococcal polysaccharide vaccine ( PPV ) manufacture Sinovac Biotech Co. , Ltd . The primary objective study demonstrate immunogenicity investigational vaccine non-inferior commercialized 23-valent PPV manufacture Chengdu Institute Biological product Co. , Ltd. ; secondary objective ass safety investigational control vaccine . Participants group three cohort age : child cohort ( 2 - 17 year old ) , adult cohort ( 18 - 60 year old ) elderly cohort ( ≥ 61 year old ) . In cohort , participant randomly assign experimental group control group ratio 1:1 .</detailed_description>
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Healthy volunteer ≥ 2 year old ; Proven legal identity ; Written consent guardian participant &lt; 18 year old , write consent participant ≥ 12 year old ; Complying requirement study protocol ; Prior vaccination pneumococcal vaccine ; History bacterial pneumonia within 3 year prior study ; Pregnant , breast feeding , woman expect conceive within 60 day vaccination ; History allergy vaccine vaccine ingredient ; Receipt follow product : 1 . Blood product within 3 month prior study entry ; 2 . Any live attenuate vaccine within 28 day prior study entry ; 3 . Any subunit vaccine inactivate vaccine within 14 day prior study entry ; 4 . Any immunosuppressant within 6 month prior study entry ; Congenital malformation , developmental disorder , serious chronic disease , autoimmune disease , immunodeficiency , serious cardiovascular disease , diabetes , hypertension stabilize medication , liver kidney disease , malignant tumor ; History asthma , thyroidectomy , angioneurotic edema , severe nervous system disease mental illness ; without spleen splenectomy ; diagnose coagulation function abnormal ( e.g. , coagulation factor deficiency , coagulation disorder , platelet abnormality ) , obvious bruise coagulation disorder ; Acute disease acute stage chronic disease within 7 day prior study entry ; Axillaty temperature &gt; 37.0 °C ; Any factor opinion investigator suggest volunteer unsuitable study ; Participants follow condition day 0 28 would include full analysis set ( FAS ) , would exclude per protocol set ( PPS ) : 1 . Receipt investigational unregistered product ( drug vaccine ) ; 2 . Receipt immunosuppressant ( corticosteroid dosage equivalent 0.5 mg prednisone/kg weight/day ) &gt; 14 day , except inhalant locally administrate corticosteroid ; 3 . Receipt immunoglobulin and/or blood product ; 4 . Newly diagnose autoimmune disease immunodeficiency ( e.g. , HIV infection ) ;</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>